Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 1/20 | 0.52 |
| ▸ | TNK2 | Q07912 | 13/20 | 0.50 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.50 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.50 |
| ▸ | PAK4 | O96013 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCND2 | P30279 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.46 |
| ▸ | PAK3 | O75914 | 2/20 | 0.46 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14682027 | 0.85 | TNK2 (0.49) | WEE1TNK2PAK1PKN1PAK4 | |
| SCHEMBL15036053 | 0.77 | FGFR4 (0.51) | WEE1TNK2PAK1PKN1PAK4 | |
| SCHEMBL13553725 | 0.74 | WEE1 (0.49) | WEE1TNK2PAK1PKN1PAK4 | |
| SCHEMBL14693020 | 0.74 | WEE1 (0.49) | WEE1TNK2PAK1PKN1PAK4 | |
| SCHEMBL15041775 | 0.73 | WEE1 (0.62) | WEE1TNK2PAK1PKN1PAK4 | |
| SCHEMBL10192790 | 0.73 | WEE1 (0.77) | WEE1TNK2PAK1PKN1PAK4 | |
| SCHEMBL13553616 | 0.73 | PAK4 (0.48) | WEE1TNK2PKN1PAK4 | |
| SCHEMBL15041459 | 0.73 | WEE1 (0.64) | WEE1TNK2PAK1PKN1PAK4 | |
| SCHEMBL15785360 | 0.72 | WEE1 (0.51) | WEE1TNK2PAK1PKN1PAK4 | |
| SCHEMBL30019212 | 0.72 | STAT6 (0.62) | PAK1PKN1PAK4FGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | WEE1 545/4885TNK2 7/4885PAK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.